Wockhardt ltd

Powered wockhardt ltd. Wockhardt Ltd Wockhardt is a pharmaceutical company that manufactures and markets vaccines, active pharmaceutical ingredients, formulations and biosimilars. Its product portfolio caters to various therapeutic areas including orthopedics, dental care, dermatology, rheumatology, gynecology, pediatrics, cardiology, pain management, nephrology, neurology and diabetes. Wockhardt is headquartered in Mumbai, wockhardt ltd, Maharashtra, India.

Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals creams and ointments. Market Position The Co. Please exercise caution and do your own analysis. Consolidated Figures in Rs. Classifications such as banks and foreign portfolio investors were not available earlier.

Wockhardt ltd

Being different and making a difference. That sums up the vision, philosophy, conviction and driving force behind Dr. Habil F Khorakiwala who revels in venturing down the road less travelled. He founded Wockhardt in Our investors, Wockhardt shareowners, are an important and valued constituent of the Wockhardt stakeholder universe. While it is a matter of regulatory compliance, we also consider it as good governance and our duty and responsibility, to keep our investors informed and updated regularly about news, events and developments that impact our business and operations. Wockhardt is a leading, research-based, global enterprise with relevance in the fields of pharmaceuticals, biotechnology, and healthcare services. WCK administered on compassionate ground and saved 20 lives. Now in Global phase III clinical trial. New Drug Discovery. Biologicals in Diabetes. Branded Pharmaceuticals. My incredible year journey with Wockhardt has been nothing short of phenomenal.

Contact the team or request a demo to find out how our data can drive your business forward. Zydus Life.

The Estimates data displayed by Moneycontrol is not a recommendation to buy or sell any securities. The Company advises the users to check with duly registered and qualified advisors before taking any investment decision. The Company or anyone involved with the Company will not accept any liability for loss or damage as a result of reliance on the Estimates data. Note : Support and Resistance level for the day, calculated based on price range of the previous trading day. Note : Support and Resistance level for the week, calculated based on price range of the previous trading week. Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.

As a research-based pharmaceutical company with a global manufacturing and marketing footprint, we manufacture and supply branded and generic finished formulations, as well as intermediate products like APIs, worldwide. Our presence across the pharmaceutical value chain is complemented by our successful venture in healthcare where we have set up a chain of 6 super specialty tertiary care hospitals with an unmatched reputation for quality and life-saving and life-enhancing medical outcomes. In addition, EMROK is enriched with several other patient-centric features such as freedom from on-therapy safety parameter monitoring and need for dose adjustments in patients with renal and hepatic function impairments as well as minimal drug-drug interaction facilitating co-medication with other drugs without safety or efficacy risk. EMROK is formally approved for acute bacterial skin and skin structure infections including diabetic-foot-infections and concurrent bacteraemia caused by Gram positive pathogens including MRSA. This was scientifically a challenge as the goal was to evolve an oral drug with a pharmacokinetic profile mimicking the injectable WCK and safety commensurate to prolonged treatment required for certain recalcitrant MRSA infections and use in out-patient settings. Safety assessments based on clinical studies approx. Globally as well as in India, in terms of disease burden, community-acquired bacterial pneumonia CABP is one of the top-ranking infections. Its management is particularly challenging due to growing resistance to current 1st line antibiotics, their safety limitations and compliance-challenging longer dosing regimen. The treatment of respiratory infections in the out-patient settings is further complicated in older age patients and children; the most vulnerable segment of patients.

Wockhardt ltd

We solicit your whole-hearted support in helping the Company implement this initiative in the interest of environment, which is the need of the hour. AGM Speech. Letter to shareowners. Financials at a Glance.

Nhs lake macquarie

Branded Pharmaceuticals. Right Issue. My ten-year tenure with Wockhardt, a global pioneer in pharmaceuticals and biotechnology, has been a remarkable journey of growth and learning. It produces formulations , biopharmaceuticals , nutrition products, vaccines and active pharmaceutical ingredients APIs. Powered by. Retrieved 13 February Retrieved 10 October Wockhardt Hospitals. The company sells 23 products under generic segment in US market. Wockhardt Foundation.

Habil Khorakiwala founded Wockhardt in

All Time High 1, Wockhardt Foundation Associate Entity. Get more out of Moneycontrol, Go Pro! The Times of India. Promoter Holding High but Pledged. Wockhardt Foundation implements several social initiatives to improve the quality of life of the underprivileged sections of society and manages to make a difference to over four million lives every year. Market Position The Co. Industries We Cover Your curated industry news round-up. Select Item. Companies with increasing Debt to Equity Ratio. View Wockhardt Ltd financials. Quarterly Annually.